Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.58 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.57 |
| ▸ | CTSD | P07339 | 2/20 | 0.49 |
| ▸ | CTSE | P14091 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371161 | 1.00 | BACE1 (0.58) | BACE1KCNH2BACE2CTSDCTSE | |
| SCHEMBL2519136 | 0.95 | BACE1 (0.65) | BACE1KCNH2BACE2CTSDCTSE | |
| SCHEMBL2519143 | 0.95 | BACE1 (0.65) | BACE1KCNH2BACE2CTSDCTSE | |
| SCHEMBL2382083 | 0.95 | BACE1 (0.65) | BACE1KCNH2BACE2CTSDCTSE | |
| SCHEMBL2371523 | 0.93 | BACE1 (0.66) | BACE1KCNH2BACE2CTSDCTSE | |
| SCHEMBL2371541 | 0.93 | BACE1 (0.66) | BACE1KCNH2BACE2CTSDCTSE | |
| SCHEMBL12235326 | 0.86 | BACE1 (0.54) | BACE1KCNH2BACE2CTSDCTSE | |
| SCHEMBL12235959 | 0.86 | BACE1 (0.54) | BACE1KCNH2BACE2CTSDCTSE | |
| SCHEMBL15418670 | 0.83 | BACE1 (0.51) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL15418739 | 0.83 | BACE1 (0.51) | BACE1KCNH2BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | BACE1 1/4885KCNH2 3129/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.